Risk Assessment of Competing Treatment Risks in Multimorbidity

Abstract

Multimorbidity, the coexistence of two or more chronic diseases in an individual, poses significant challenges in clinical risk assessment and management. Competing treatment risks where therapies for one condition may increase risks for another complicate evidence-based decision-making. This review synthesizes current epidemiological data, pathophysiological mechanisms, and risk stratification strategies, emphasizing the importance of individualized care. Recent advances in risk prediction models, shared decision-making, and guideline recommendations are discussed, offering clinicians practical insights for optimizing outcomes in patients with multimorbidity.

Introduction

The prevalence of multimorbidity is increasing globally, paralleling aging populations and advances in chronic disease management. In clinical practice, the presence of multiple coexisting conditions often necessitates complex therapeutic regimens. However, treatments beneficial for one disease may adversely impact another, introducing the concept of competing treatment risks. Risk assessment in this context requires nuanced understanding of disease interactions, pharmacological effects, and patient-centered priorities. This article provides a comprehensive review of the science and practice of risk assessment in multimorbidity, with a focus on evidence-based strategies for minimizing iatrogenic harm while maximizing clinical benefit.

Epidemiology / Disease Burden

Multimorbidity affects an estimated 65% of adults over 65 years and approximately one in four adults overall. The burden is particularly high in primary care and is associated with increased healthcare utilization, polypharmacy, and reduced quality of life. Studies from the UK Biobank and US NHANES cohorts underscore the rising incidence, with socioeconomic deprivation and age as significant predictors. The high prevalence of multimorbidity amplifies the complexity of clinical care, with data showing a direct correlation between the number of chronic diseases and both mortality and hospitalization rates.

Pathophysiology

Multimorbidity arises through shared pathophysiological pathways, including chronic low-grade inflammation, oxidative stress, and neurohormonal dysregulation. For example, diabetes, cardiovascular disease, and chronic kidney disease frequently co-occur via vascular and metabolic mechanisms. The interplay of disease processes can exacerbate individual conditions and alter drug pharmacodynamics and pharmacokinetics. These interactions often lead to cumulative organ dysfunction and heightened vulnerability to adverse drug reactions, particularly in the elderly and those with frailty.

Risk Factors

Risk factors for developing multimorbidity and experiencing competing treatment risks include advanced age, genetic predisposition, lifestyle behaviors (such as smoking and physical inactivity), and social determinants of health. Polypharmacy, defined as the use of five or more medications, is a primary driver of treatment-related risk, increasing the likelihood of drug-drug and drug-disease interactions. Comorbid mental health disorders, such as depression and cognitive impairment, further complicate risk assessment and management by impacting adherence and self-management capacity.

Clinical Features

Patients with multimorbidity often present with non-specific symptoms such as fatigue, functional decline, and cognitive disturbances, complicating clinical evaluation. The classical manifestations of individual diseases may be obscured or altered by the presence of other conditions or by pharmacological interventions. For instance, beta-blockers may mask hypoglycemia symptoms in diabetic patients, while NSAIDs used for osteoarthritis can exacerbate hypertension or renal dysfunction. Recognizing atypical presentations and understanding the full clinical context are critical for accurate risk stratification.

Diagnosis

Diagnosis in multimorbidity demands a comprehensive, patient-centered approach. Standard diagnostic criteria for individual diseases may not fully capture the complexity of overlapping syndromes. Tools such as the Cumulative Illness Rating Scale (CIRS) and the Charlson Comorbidity Index (CCI) are used to quantify disease burden, while medication review and reconciliation are essential to identify potential iatrogenic risks. Clinical judgment, multidisciplinary input, and judicious use of laboratory and imaging studies are vital in balancing diagnostic thoroughness with the avoidance of over-investigation.

Treatment & Management

Management strategies in multimorbidity must prioritize patient-centered goals and minimize potential harms. Key principles include regular medication review, deprescribing where appropriate, and the use of non-pharmacological interventions such as exercise and dietary modification. Shared decision-making is paramount, with attention to patient values, quality of life, and life expectancy. Integrated care models, involving collaboration between primary care, specialists, pharmacists, and allied health professionals, have demonstrated improved outcomes in this population.

Recent Advances / Emerging Therapies

Recent advances include the development of risk prediction models that incorporate multimorbidity and treatment interactions, such as the Multimorbidity Treatment Burden Index and individualized risk calculators. Digital health tools, including electronic health records with clinical decision support, now aid clinicians in identifying potential drug-drug and drug-disease interactions at the point of care. Emerging therapies, such as SGLT2 inhibitors, offer benefits across multiple comorbid conditions (e.g., diabetes, heart failure, CKD) and exemplify the trend toward therapeutics with pleiotropic effects and lower competing risk profiles.

Guideline Recommendations

Recent guidelines from organizations such as NICE and the American Geriatrics Society emphasize individualized care plans, regular medication review, and the avoidance of rigid disease-based protocols in patients with multimorbidity. The focus is shifting toward holistic assessment, functional status, and patient preferences. Recommendations include the use of screening tools for frailty and cognitive impairment, proactive deprescribing, and close monitoring for adverse effects. Multidisciplinary team-based care and structured care transitions are strongly advocated to reduce the risk of treatment-related harm.

Conclusion

Risk assessment of competing treatment risks in multimorbidity requires a multidimensional, evidence-based approach. Clinicians must integrate epidemiological data, pathophysiological understanding, and advanced risk stratification tools with patient-centered care principles. Recent advances in predictive modeling and guideline recommendations offer practical frameworks for minimizing harm and optimizing therapeutic outcomes. Ongoing research, interdisciplinary collaboration, and continued emphasis on shared decision-making are essential to meet the needs of this complex and growing patient population.